What have animal models taught us about the p53 pathway?

Journal of Pathology

Volumn 205, Issue 2, 2005, Pages 206-220

  Lozano, Guillermina ^a   Zambetti, Gerard P ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Knockin; Knockout; p53 mediators; p53 regulators

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CASEIN KINASE II; CASPASE 9; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN BAX; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P19; PROTEIN P53; PROTEIN P63; PROTEIN P73; TUMOR SUPPRESSOR PROTEIN;

BREAST CANCER; CARCINOGENESIS; CELL CYCLE; CELL DEATH; EXPERIMENTAL MODEL; GENE ACTIVATION; GENE ACTIVITY; GENE LOCUS; GENE MUTATION; GENETIC REGULATION; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; MISSENSE MUTATION; MITOSIS INHIBITION; MOUSE; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SPLEEN CANCER;

ANIMALS; APOPTOSIS; CELL CYCLE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MICE; MUTATION, MISSENSE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13644264337     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1704     Document Type: Review

References (148)

1. Kwan KM. Conditional alleles in mice: practical considerations for tissue-specific knockouts. Genesis 2002; 32 49-62.
2. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis 2000; 26: 99-109.
3. Branda CS, Dymecki SM. Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev Cell 2004; 6: 7-28.
4. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111-1116.
5. Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003; 4: 181-189.
6. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
7. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999; 55: 48-63.
8. Donehower LA. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol 1996; 7: 269-278.
9. Lozano G, Liu G. Mouse models dissect the role of p53 in cancer and development. Semin Cancer Biol 1998; 8: 337-344.
10. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-126.
11. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
12. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003; 1: 993-1000.
13. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461-468.
14. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-1132.
15. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
16. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
17. Chavez-Reyes A, Parant JM, Amelse LL, et al. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res 2003; 63: 8664-8669.
18. Grier JD, Yan W, Lozano G. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis 2002; 32: 145-147.
19. Steinman HA, Jones SN. Generation of an Mdm2 conditional allele in mice. Genesis 2002; 32: 142-144.
20. Mendrysa SM, McElwee MK, Michalowski J, et al mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 2003; 23: 462-472.
21. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haploinsufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J 2003; 22: 1442-1450.
22. Momand J, Zambetti GP. Mdm-2: 'big brother' of p53. J Cell Biochem 1997; 64: 343-352.
23. Jones SN, Hancock AR, Vogel H, et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 1998; 95: 15 608-15 612.
24. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
25. Shvarts A, Steegenga WT, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15: 5349-5357.
26. Finch RA, Donoviel DB, Potter D, et al mdmx is a negative regulator of p53 activity in vivo. Cancer Res 2002; 62 3221-3225.
27. Migliorini D, Denchi EL, Danovi D, et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 2002; 22: 5527-5538.
28. Parant J, Chavez-Reyes A, Little NA, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet 2001; 29: 92-95.
29. Riemenschneider MJ, Buschges R, Wolter M, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999; 59: 6091-6096.
30. Danovi D, Meulmeester E, Pasini D, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004; 24: 5835-5843.
31. Ramos YF, Stad R, Attema J, et al. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001; 61: 1839-1842.
32. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997; 15: 177-202.
33. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268: 1749-1753.
34. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
35. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506.
36. Kastan MB, Lim DS. The many substrates and functions of ATM. Nature Rev Mol Cell Biol 2000; 1: 179-186.
37. Siliciano JD, Canman CE, Taya Y, et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11: 3471-3481.
38. Sakaguchi K, Herrera JE, Saito S, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998; 12: 2831-2841.
39. Xu Y, Ashley T, Brainerd EE, et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 1996; 10 2411-2422.
40. Westphal CH, Schmaltz C, Rowan S, et al. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res 1997; 57 1664-1667.
41. Barlow C, Brown KD, Deng CX, et al. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nature Genet 1997; 17: 453-456.
42. Herzog KH, Chong MJ, Kapsetaki M, et al. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 1998; 280: 1089-1091.
43. Zamariri-Davis F, Zambetti GP. p53-tumor suppressor genes. In Cell Cycle and Growth Control: Biomolecular Regulation and Cancer, Stein GS, Pardee AB (eds). Wiley-Liss: Hoboken, NJ, 2004; 635-666.
44. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-334.
45. Sluss HK, Armata H, Gallant J, Jones SN. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 2004; 24: 976-984.
46. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429.
47. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-953.
48. Shieh SY, Ahn J, Tamai K, et al. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000; 14: 289-300.
49. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A 1999; 96: 13 777-13 782.
50. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286 2528-2531.
51. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
52. Srivastava S, Zou ZQ, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749.
53. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(* -1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet 2002; 31: 55-59.
54. Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71: 432-438.
55. Takai H, Naka K, Okada Y, et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002; 21: 5195-5205.
56. Hirao A, Cheung A, Duncan G, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002; 22: 6521-6532.
57. MacPherson D, Kim J, Kim T, et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J 2004; 23: 3689-3699.
58. Keller DM, Zeng X, Wang Y, et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell 2001; 7: 283-292.
59. Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A 1998; 95: 2834-2837.
60. Lu H, Taya Y, Ikeda M, Levine AJ. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc Natl Acad Sci U S A 1998; 95: 6399-6402.
61. Buchou T, Verner M, Blond O, et al. Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 2003; 23: 908-915.
62. Bruins W, Zwart E, Attardi LD, et al. Increased sensitivity to UV radiation in mice with a p53 point mutation at ser389. Mol Cell Biol 2004; 24: 8884-8894.
63. Iwakuma T, Parant JM, Fasulo M, et al. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene 2004; 23: 7644-7650.
64. Sherr CJ. The INK4a/ARF network in tumour suppression. Nature Rev Mol Cell Biol 2001; 2: 731-737.
65. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
66. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
67. Kamijo T, Weber JD, Zambetti G, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998; 95: 8292-8297.
68. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659.
69. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424-2433.
70. de Stanchina E, McCurrach ME, Zindy F, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998; 12: 2434-2442.
71. Kamijo T, Bodner S, van de Kamp E, et al. Tumor spectrum in ARF-deficient mice. Cancer Res 1999; 59: 2217-2222.
72. Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27-37.
73. Krimpenfort P, Quon KC, Mooi WJ, et al. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413: 83-86.
74. Satyamoorthy K, Herlyn M. p16INK4A and familial melanoma. Methods Mol Biol 2003; 222: 185-195.
75. Eischen CM, Weber JD, Roussel MF, et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
76. Schmitt CA, McCurrach ME, de Stanchina E, et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13: 2670-2677.
77. Pietenpol JA, Vogelstein B. Tumour suppressor genes. No room at the p53 inn. Nature 1993; 365: 17-18.
78. Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays 2000; 22: 728-737.
79. Ouchi T, Monteiro AN, August A, et al. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 1998; 95 2302-2306.
80. Zhang H, Somasundaram K, Peng Y, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998; 16: 1713-1721.
81. MacLachlan TK, Takimoto R, El-Deiry WS. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 2002; 22: 4280-4292.
82. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781-794.
83. Moynahan ME. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene 2002; 21: 8994-9007.
84. Xu X, Qiao W, Linke SP, et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nature Genet 2001; 28: 266-271.
85. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genet 1999; 22: 37-43.
86. Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A 1998; 95: 13 869 -13 874.
87. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997; 11: 1226-1241.
88. Jonkers J, Meuwissen R, van der Gulden H, et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet 2001; 29: 418-425.
89. Greenblatt MS, Chappuis PO, Bond JP, et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germline mutations: distinctive spectrum and structural distribution. Cancer Res 2001; 61: 4092-4097.
90. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004; 2: 371-386.
91. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nature Rev Mol Cell Biol 2000; 1: 199-207.
92. Mills AA, Zheng B, Wang XJ, et al p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-713.
93. Celli J, Duijf P, Hamel BC, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999; 99: 143-153.
94. Flores ER, Tsai KY, Crowley D, et al p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 560-564.
95. Senoo M, Manis JP, Alt FW, McKeon F. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 2004; 6: 85-89.
96. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219.
97. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
98. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80 293-299.
99. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997; 389: 300-305.
100. Knudson CM, Tung KS, Tourtellotte WG, et al. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995; 270: 96-99.
101. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852.
102. Lowe SW, Schmitt EM, Smith SW, et al p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
103. Chong MJ, Murray MR, Gosink EC, et al. Atm and Bax cooperate in ionizing radiation-induced apoptosis in the central nervous system. Proc Natl Acad Sci U S A 2000; 97: 889-894.
104. Lindsten T, Ross AJ, King A, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-1399.
105. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694.
106. Yu J, Zhang L, Hwang PM, et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-682.
107. Han J, Flemington C, Houghton AB, et al. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci U S A 2001; 98: 11 318-11 323.
108. Yu J, Wang Z, Kinzler KW, et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 2003; 100: 1931-1936.
109. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
110. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4: 321-328.
111. Melino G, Bernassola F, Ranalli M, et al p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 2004; 279: 8076-8083.
112. Liu G, Parant JM, Lang G, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genet 2004; 36: 63-68.
113. Hemann MT, Zilfou JT, Zhao Z, et al. Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A 2004; 101: 9333-9338.
114. Mihara M, Erster S, Zaika A, et al p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577-590.
115. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014.
116. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
117. Shibue T, Takeda K, Oda E, et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 2003; 17: 2233-2238.
118. Adams JM, Cory S. Apoptosomes: engines for caspase activation. Curr Opin Cell Biol 2002; 14: 715-720.
119. Moroni MC, Hickman ES, Denchi EL, et al. Apaf-1 is a transcriptional target for E2F and p53. Nature Cell Biol 2001; 3 552-558.
120. Soengas MS, Alarcon RM, Yoshida H, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284: 156-159.
121. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
122. Hakem R, Hakem A, Duncan GS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998; 94: 339-352.
123. Yoshida H, Kong YY, Yoshida R, et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 1998; 94: 739-750.
124. Marsden VS, O'Connor L, O'Reilly LA, et al. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419: 634-637.
125. Scott CL, Schuler M, Marsden VS, et al. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J Cell Biol 2004; 164 89-96.
126. Attardi LD, Reczek EE, Cosmas C, et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 2000; 14: 704-718.
127. Ihrie RA, Reczek E, Homer JS, et al. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol 2003; 13: 1985-1990.
128. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16: 4952-4960.
129. Rowan S, Ludwig RL, Haupt Y, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996; 15: 827-838.
130. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
131. Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552-557.
132. Deng C, Zhang P, Harper JW, et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
133. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234-6238.
134. Shiohara M, el-Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-3784.
135. Gao X, Chen YQ, Wu N, et al. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 1995; 11: 1395-1398.
136. de Vries A, Flores ER, Miranda B, et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A 2002; 99: 2948-2953.
137. Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Hum Mutat 2003; 21: 321-326.
138. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355.
139. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-1093.
140. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ 1990; 1: 571-580.
141. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nature Genet 1993; 4: 42-46.
142. Slingerland JM, Jenkins JR, Benchimol S. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J 1993; 12: 1029-1037.
143. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60: 6788-6793.
144. Liu G, McDonnell TJ, Montes de Oca Luna R, et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A 2000; 97: 4174-4179.
145. Lang GA, Iwakuma T, Suh YA, et al. Gain-of-function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119.
146. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain-of-function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119.
147. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112: 779-791.
148. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429: 86-92.